The Future of Blue Biotechnology
Blue biotechnology is moving from a “promising niche” to an enabling pillar of the blue economy—because it converts aquatic biodiversity and biomass into high-value products and services while supporting Europe’s climate, resilience, and competitiveness objectives.
At its core, blue biotechnology applies science and technology to living aquatic organisms—including microalgae, bacteria, fungi, algae and marine invertebrates—to generate knowledge, goods, and services. This scope matters: it expands the innovation frontier beyond traditional marine harvesting into bio-based manufacturing, new biomaterials, and bioactive compounds that can feed multiple markets.
1) What blue biotechnology is—and where it shows up in the market
The European Commission frames the wider “blue bioeconomy” as the transformation of aquatic biomass into food and feed, nutraceuticals, pharmaceuticals, cosmetics, energy, packaging, textiles, and more. That breadth is precisely why blue biotechnology is strategic: it can create high value-added outputs (for example, bioactive compounds for health applications and specialized ingredients for cosmetics and nutraceuticals) while also contributing to industrial decarbonisation through bio-based substitutes.
A particularly important pipeline is algae. The Commission highlights algae’s versatility across pharmaceuticals, healthier food products, substitutes for fish oil in feed, cosmetic and personal-care inputs, biofertilizers, bio-packaging, and even biofuels. It also notes emerging “co-benefits” when seaweed aquaculture is well designed—such as nutrient removal, carbon sequestration potential, habitat support, and coastal resilience.
This is not only a technology story; it is also an economic one. According to the EU Blue Economy Observatory, the EU blue biotechnology sector generated EUR 327 million in gross value added (GVA) in 2022, with EUR 942 million in turnover, and around 2,400 people directly employed—with estimates suggesting continued growth into 2023. Even if the absolute size is still modest compared to mature blue economy sectors, the trajectory signals a market that is consolidating, professionalising, and preparing to scale.
2) Innovation landscape: research strength, startups, and enabling infrastructure
Europe’s advantage in blue biotechnology is built on a strong R&I base and expanding innovation ecosystems. The Commission explicitly notes that the blue bioeconomy is developing fast and benefits from EU research and stakeholder engagement—while acknowledging uneven development across regions, which is exactly where policy and investment can make the difference.
From a competitiveness perspective, the EU is also sharpening its framing: the EU Blue Economy Report 2025 broadened its analytical scope to include blue biotechnology as a distinct sector, which is a strong signal that the EU wants better visibility on performance, drivers, and investment needs. The same report points to sustained investment dynamics across blue economy sectors, with activities such as blue biotechnology showing steady annual growth in investment over the long term—reinforcing the importance of continued R&D funding and scale-up capital.
A defining feature of the current innovation landscape is the shift from “discovery” to “deployment”:
● Discovery and characterisation (genomics, bioinformatics, screening of marine organisms for novel compounds),
● Process development (fermentation, cultivation, extraction and purification),
● Industrialisation (biorefineries, quality systems, regulatory compliance, and supply-chain repeatability),
● Market formation (buyer trust, standards, and procurement pathways).
The Observatory also points to the role of technological advances (biotech, genomics, bioinformatics) in enabling discovery and new bioprocessing techniques—i.e., innovation is increasingly platform-driven.
3) Policy outlook: EU Bioeconomy Strategy and blue economy priorities
The policy environment is becoming more explicitly “pro-innovation, pro-scale.” The European Commission’s 2025 Strategy for a Competitive and Sustainable EU Bioeconomy sets objectives that map directly onto blue biotech’s needs: scaling and commercialising biotech solutions, increasing circular and resource-efficient use of biological resources, and positioning the EU in expanding international markets for bio-based materials and biomanufacturing.
Importantly, the accompanying Commission communication (COM/2025/960) emphasises measures that are highly relevant to blue biotech scale-up: improving access to finance for startups and scale-ups (including via EIC instruments and cooperation with financial actors), and promoting test environments such as regulatory sandboxes to keep regulation supportive of innovation.
On the “blue economy” side, the Commission also stresses the need for a level playing field and coordinated stakeholder action. In algae specifically, the EU initiative sets out 23 actions to strengthen governance and legal frameworks, improve business environments, raise social awareness and acceptance, and close knowledge and technology gaps. This is the kind of targeted policy scaffolding that can reduce fragmentation and accelerate market uptake.
4) The future: where the sector is going next
The next phase of blue biotechnology is likely to be defined by platform scaling, industrial integration, and policy-enabled market formation.
- From single products to biomanufacturing platforms. Instead of “one organism → one compound,” the winning models will increasingly resemble modular platforms: standardized cultivation/fermentation, flexible downstream processing, and multi-product portfolios. This reduces risk and improves unit economics—especially for SMEs and scale-ups.
- Algae as a strategic value chain. Algae will keep expanding as a cross-sector feedstock and ingredient base—from food and feed to packaging and cosmetics—while policy actions seek to harmonise governance and close tech gaps.
- More investable pipelines and scale-up support. With the EU bioeconomy strategy prioritising scale-up and investment security, and highlighting improved access to finance and innovation-friendly test environments, the direction of travel is clear: fewer pilots stranded at TRL 6–7, and more routes to commercial production.
- A stronger “ocean responsibility” license to operate. Blue biotech will increasingly be expected to show credible sustainability performance—not just in end products, but in sourcing, biodiversity safeguards, and alignment with ocean governance frameworks. The BBNJ agreement and ocean state reporting ecosystems reinforce that governance expectations are rising.
Blue biotechnology is no longer a speculative frontier. It is becoming a strategic industrial and innovation domain—linking ocean biodiversity to health, materials, and climate-resilient value chains. The EU’s own measurement of the sector, combined with its 2025 bioeconomy strategy focus on scale-up, investment security, and innovation-friendly regulation, suggests the next decade will be about turning scientific advantage into industrial capacity—while operating inside a tightening ocean sustainability and governance context.
Are you looking for a job in this sector? Register at Blue Jobs to discover opportunities and connect with companies in the blue economy.
If you want to learn more about this topic, you can also watch our webinar:
https://www.youtube.com/watch?v=Ro8B47VsE1Y
Sources:
https://www.un.org/bbnjagreement/en
https://www.fao.org/fishery/en/openasfa/a7e56d8b-a43e-4c2e-bed4-78e47e310aa7
https://www.oecd.org/en/publications/marine-biotechnology_9d0e6611-en.html
